(Q33762423)

English

Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1 reference

ChEBI release 2020-05-28

metastatic breast cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

6

object named as

Jacek Jassem

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Gabriel N Hortobagyi

9

object named as

Gabriel N Hortobagyi

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

3

object named as

Edith A Perez

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

4

object named as

Joseph A Sparano

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Pierfranco Conte

2

object named as

Pierfranco Conte

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

author name string

Henri Roché

1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Binghe Xu

5

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Ronald Peck

7

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Thomas Kelleher

8

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

language of work or name

0 references

publication date

3 December 2010

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

125

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

755-765

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Extending survival with chemotherapy in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1251-Y

21 January 2018

Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1251-Y

21 January 2018

The role of capecitabine in first-line treatment for patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1251-Y

21 January 2018

Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1251-Y

21 January 2018

Symptom prevalence, characteristics and distress in a cancer population.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1251-Y

21 January 2018

Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1251-Y

21 January 2018

Preclinical discovery of ixabepilone, a highly active antineoplastic agent

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1251-Y

21 January 2018

Preclinical efficacy spectrum and pharmacokinetics of ixabepilone

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1251-Y

21 January 2018

Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1251-Y

21 January 2018

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1251-Y

21 January 2018

Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1251-Y

21 January 2018

Ixabepilone in combination with capecitabine and as monotherapy for treatment of advanced breast cancer refractory to previous chemotherapies

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1251-Y

21 January 2018

Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1251-Y

21 January 2018

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1251-Y

21 January 2018

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1251-Y

21 January 2018

A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1251-Y

21 January 2018

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1251-Y

21 January 2018

Identifiers

10.1007/S10549-010-1251-Y

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33762423&oldid=2195754195"